Here are 1-2 brief analogies to describe Beam Therapeutics:

• Beam Therapeutics is like Moderna for genetic disease cures, using a revolutionary DNA editing technology.
• Imagine CRISPR Therapeutics, but with a more precise 'base editing' technology to fix genetic diseases.

• BEAM-101: A genetic medicine candidate for the treatment of sickle cell disease and beta thalassemia.
• BEAM-102: A genetic medicine candidate specifically targeting the treatment of sickle cell disease.
• BEAM-201: An allogeneic chimeric antigen receptor T cell (CAR-T) therapy for relapsed/refractory T-cell acute lymphoblastic leukemia.
• BEAM-301: A liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia.

Beam Therapeutics primarily generates revenue through collaborations, partnerships, and licensing agreements with other biotechnology and pharmaceutical companies. As a biotechnology company in the development stage, it does not currently sell commercial products directly to individual patients or healthcare providers.

Its major customers and partners, based on the agreements described, include:

• Sana Biotechnology, Inc.
• Pfizer Inc. (PFE)
• Apellis Pharmaceuticals, Inc. (APLS)
• Verve Therapeutics, Inc. (VERV)

Sana Biotechnology, Inc. (SANA)

Verve Therapeutics, Inc. (VERV)

John Evans, Chief Executive Officer and Board Member

John Evans joined Beam Therapeutics in 2017 as Chief Executive Officer and a director. He has extensive experience in company-building, corporate development, and drug development within the biotechnology industry. Prior to Beam, Mr. Evans was an early employee and a member of the leadership team at Agios Pharmaceuticals, most recently serving as Senior Vice President for Corporate Development and Portfolio Leadership. At Agios, he provided strategic and operational leadership for a portfolio of IDH inhibitors, including IDHIFA and TIBSOVO, and helped lead Agios' alliance with Celgene. He also co-led Agios' expansion into rare genetic diseases. Before Agios, Mr. Evans worked at Infinity Pharmaceuticals, McKinsey & Company (Pharmaceuticals practice), and MedImmune. Mr. Evans served as interim CEO for Prime Medicine Inc. and continues to serve on its board. He also held a Venture Partner role at ARCH Venture Partners LLC from April 2017 to March 2021, a firm that invests in early-stage biotechnology companies. Additionally, he is on the board of Verve Therapeutics, Inc. and Orbital Therapeutics, Inc.

Sravan Emany, Chief Financial Officer

Sravan Emany was appointed Chief Financial Officer of Beam Therapeutics, effective December 19, 2024. He previously served as CFO and Chief Operating Officer at Ironwood Pharmaceuticals, Inc. Before Ironwood, Mr. Emany held roles as Corporate Vice President, Commercial Excellence and Chief Strategy Officer, and Vice President of Strategy, Treasury and Investor Relations at Integra LifeSciences Holdings Corporation. Earlier in his career, he spent nearly a decade in various mergers and acquisitions investment banking roles at Bank of America and BofA Securities, where he became a Managing Director and led numerous healthcare M&A transactions.

Giuseppe Ciaramella, Ph.D., President

Dr. Giuseppe Ciaramella is the President of Beam Therapeutics. He was previously the President and Chief Scientific Officer from 2020 to 2023, and Chief Scientific Officer from 2018 to 2020. Dr. Ciaramella brings over 20 years of drug discovery experience from leading pharmaceutical companies. He served as the Chief Scientific Officer of the Infectious Diseases division at Moderna Therapeutics, where he was instrumental in developing some of the first mRNA vaccines for human dosing. His career also includes leadership positions at AstraZeneca, Boehringer Ingelheim, Pfizer, and Merck, with a focus on antivirals, immunology, and biotherapeutics. At Pfizer, he held several Discovery leadership roles, including head of Biotherapeutics, Antivirals, and Lead Discovery, and contributed to the development of the anti-HIV drug Maraviroc (Selzentry™). He is also a co-founder and CEO of Orbital Therapeutics since 2022.

Amy Simon, M.D., Chief Medical Officer

Dr. Amy Simon serves as the Chief Medical Officer at Beam Therapeutics.

Susan O'Connor, Chief Human Resources Officer

Susan O'Connor is the Chief Human Resources Officer at Beam Therapeutics.

The key risks to Beam Therapeutics' business are primarily associated with the inherent challenges of developing novel genetic medicines, navigating a competitive landscape, and maintaining substantial funding for its pipeline.

1. Clinical Trial and Regulatory Success: As a biotechnology company focused on precision genetic medicines, Beam Therapeutics' valuation and future success are heavily reliant on the successful progression of its drug candidates through clinical trials and ultimately obtaining regulatory approval. Any delays in patient enrollment, unexpected adverse events, or failures in clinical programs, such as BEAM-101 for sickle cell disease or BEAM-302 for alpha-1 antitrypsin deficiency, would significantly impact the company's prospects and stock price. The use of novel base editing technology also introduces heightened regulatory scrutiny and uncertainty regarding long-term safety and efficacy. For instance, a patient death in the BEAM-101 trial, though attributed to the busulfan conditioning regimen rather than the drug itself, underscores the severe risks associated with the overall treatment process for some genetic therapies.

2. Intense Competition: Beam Therapeutics operates in a highly competitive gene editing and therapy market. The company faces significant competition from established players, including those with approved products like CRISPR Therapeutics' Casgevy for sickle cell disease. Competitors with potentially more advanced therapies, greater financial resources, or superior expertise in research and development could outpace Beam Therapeutics in bringing products to market, thereby reducing its commercial opportunities and market share.

3. Financial Constraints and Funding Needs: Beam Therapeutics is a development-stage company with a history of substantial operating losses and significant research and development expenses, which are expected to continue for the foreseeable future. While the company has secured funding that extends its cash runway, it will require substantial additional capital to support ongoing development activities and advance its extensive pipeline to commercialization. Failure to secure this funding could lead to delays or reductions in crucial research and development programs and potential dilution for existing shareholders through future equity raises.

The advancement and potential clinical superiority of next-generation gene editing technologies, such as prime editing, being developed by companies like Prime Medicine, Inc. Prime editing is designed to offer a wider range of precise genetic modifications with potentially improved safety and efficacy profiles compared to Beam Therapeutics' base editing platform, particularly for indications like sickle cell disease where Beam has lead candidates. If prime editing demonstrates clear advantages in clinical development, it could diminish the competitive position of base editing as a core therapeutic modality.

Beam Therapeutics (symbol: BEAM) is developing precision genetic medicines for various serious diseases. The addressable markets for their main product candidates are substantial across global and U.S. regions.

BEAM-101 (Sickle Cell Disease and Beta Thalassemia) and BEAM-102 (Sickle Cell Disease)

• Sickle Cell Disease (SCD): The global sickle cell disease treatment market was valued at approximately USD 3.75 billion in 2025 and is projected to reach around USD 14.06 billion by 2034, expanding at a Compound Annual Growth Rate (CAGR) of 15.81% over the forecast period from 2025 to 2034. Another estimate indicates the global market size was USD 4.73 billion in 2026 and is projected to reach USD 20.47 billion by 2034, exhibiting a CAGR of 20.10%. North America held a significant market share, with the United States dominating the SCD treatment market, accounting for 63.35% in 2025. The North America sickle cell disease market, estimated at USD 1,400.2 million in 2025, is expected to reach USD 4,005.3 million by 2032.
• Beta Thalassemia: The global beta thalassemia market is projected to expand at an 8.5% CAGR, growing from USD 1.9 billion in 2024 to USD 3.1 billion by 2030. Other reports indicate the global market size was valued at USD 9.70 billion in 2024 and is expected to reach USD 17.96 billion by 2032. In the United States, the beta thalassemia market was valued at approximately USD 358 million in 2023 and is projected to expand significantly by 2034. The U.S. beta-thalassemia market captured the largest revenue share of 81% within North America in 2024. The 7 major Beta Thalassemia markets (US, EU4, UK, and Japan) reached a value of USD 368.7 Million in 2024 and are expected to reach USD 901.7 Million by 2035.

BEAM-201 (Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia)

• Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL): The global T-cell Acute Lymphoblastic Leukemia Treatment Market was valued at USD 3,254.67 million in 2025 and is expected to increase to USD 4,672.03 million by 2032, at a Compound Annual Growth Rate (CAGR) of 5.3%. North America is estimated to exhibit the highest CAGR for the T-cell Acute Lymphoblastic Leukemia Treatment Market over the forecast period of 2025-2030.

BEAM-301 (Glycogen Storage Disease Type Ia)

• Glycogen Storage Disease Type Ia (GSDIa): GSDIa is a rare inherited disorder. In the U.S., the prevalence of GSD type Ia alone is estimated at 1 in 100,000 individuals. The mean annual healthcare cost for a GSDIa patient in the U.S. is approximately $33,910 per patient in 2024. Currently, there are no FDA-approved therapies for GSD-1a. The top 7 (US, EU4, UK, and Japan) glycogen storage disease markets (encompassing all GSD types) are expected to exhibit a CAGR of 5.58% during 2025-2035.

Beam Therapeutics (BEAM) is anticipated to drive future revenue growth over the next 2-3 years through several key initiatives:

• Commercialization of Risto-cel (BEAM-101) for Sickle Cell Disease: The company anticipates submitting a Biologics License Application (BLA) for risto-cel, an investigational autologous cell therapy for sickle cell disease, as early as year-end 2026. This pivotal step towards regulatory approval and potential launch, supported by a strategic financing agreement, positions risto-cel as a significant near-term revenue driver.
• Advancement of BEAM-302 for Alpha-1 Antitrypsin Deficiency (AATD): Initial clinical data from multiple cohorts for BEAM-302, a potential one-time treatment for AATD, is expected in 2025. Plans for pivotal development are anticipated in the first quarter of 2026, suggesting a pathway to market and future revenue generation.
• Expansion of the Sickle Cell Disease Patient Population via the ESCAPE Program: Beam's ESCAPE program, which includes development candidates like BEAM-103 and BEAM-104, aims to provide non-genotoxic conditioning for ex vivo gene therapy. This approach is designed to eliminate chemotherapy and expand the eligible patient population for sickle cell disease treatments, significantly increasing the long-term market potential and associated revenues for Beam's SCD therapies.
• Progression of New Liver-Targeted Genetic Disease Programs (BEAM-301 & BEAM-304): The company expects initial data for BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) in 2026, following its first patient dosing in early 2025. Additionally, an Investigational New Drug (IND) filing for BEAM-304, a new liver-targeted program for phenylketonuria (PKU), is expected in 2026, with a Phase 1/2 trial to follow. These advancements open new therapeutic areas and represent future revenue streams as they move through clinical development.

Share Issuance

• In September 2020, Beam Therapeutics priced a public offering of 5,000,000 shares of common stock at $23.50 per share, generating gross proceeds of approximately $117.5 million.
• In October 2023, Beam received a $50 million equity investment from Eli Lilly and Company as part of a broader collaboration and license agreement.

Inbound Investments

• In January 2022, Beam Therapeutics entered into a four-year research collaboration with Pfizer Inc., receiving an upfront payment of $300 million and potentially up to $1.05 billion in future milestone payments and royalties.
• In October 2023, Eli Lilly and Company acquired Beam's opt-in rights to certain Verve Therapeutics' base editing programs, providing Beam with a $200 million upfront payment and eligibility for up to $350 million in potential future development-stage payments.
• In February 2026, Beam Therapeutics secured a strategic financing agreement with Sixth Street for a senior secured credit facility of up to $500 million, including an initial $100 million funded at close. An additional $300 million is available upon achieving certain clinical, regulatory, and commercial milestones for risto-cel.

Capital Expenditures

• Capital expenditures were $47 million in 2021, $49 million in 2022, and $34 million in 2023.
• In the fourth quarter of 2025, capital expenditures were $3.7 million.
• Beam initiated GMP operations at its North Carolina manufacturing facility, indicating a focus on expanding internal manufacturing capabilities. The company expects its capital resources to cover anticipated capital expenditure requirements into mid-2029.